New skin cancer vaccine being trialled by the NHS can halve the risk of dying or the deadly disease returning, study finds

Melanoma patients given Tecemotide alongside immunotherapy drug Keytruda were 49 per cent more likely to be alive three years later compared to those taking Keytruda alone. Melanoma patients given Tecemotide alongside immunotherapy drug Keytruda were 49 per cent more likely to be alive three years later compared to those taking Keytruda alone.